Ademi LLP is investigating the proposed sale of Bio-Techne Corporation to Merck KGaA for $73.00 per share in cash, representing a total enterprise value of approximately $11.3 billion. The investigation focuses on whether Bio-Techne's board of directors breached fiduciary duties or violated federal securities laws by failing to secure the best possible price for shareholders. Ademi LLP joins Halper Sadeh LLC, Monteverde & Associates PC, and Kahn Swick & Foti, LLC in scrutinizing the transaction's fairness and the process leading to the agreement.

The firms are examining potential conflicts of interest and whether the transaction agreement unreasonably limits competing transactions. Under the merger agreement, Bio-Techne is required to pay Merck KGaA a termination fee of $230,455,000 if the board changes its recommendation to favor a superior proposal or if the company terminates the agreement to enter into a definitive agreement for a superior proposal. The fee also applies if the agreement is terminated due to a failure to obtain shareholder approval or consummate the merger by the outside date, provided a competing proposal is announced and subsequently consummated within 12 months.

Conversely, Merck KGaA is obligated to pay Bio-Techne a reverse termination fee of $576,140,000 in two primary scenarios. The first is if the merger does not occur by the outside date despite all closing conditions, other than antitrust or investment screening approvals, being satisfied or waived. The second scenario involves a final, non-appealable order from a governmental entity permanently enjoining the merger due to antitrust or investment screening laws. This fee is not payable if Bio-Techne's failure to perform its obligations is the principal cause of the termination.

Ademi LLP raised concerns that Bio-Techne insiders will receive substantial benefits as part of change of control arrangements that may not be available to ordinary shareholders. Halper Sadeh LLC has similarly expressed concerns that the proposed transaction may contain terms limiting superior competing offers. Monteverde & Associates PC, recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report, is also examining the deal's fairness. Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is seeking to determine if the consideration and the process that led to it are adequate.

Shareholders are encouraged to contact the investigating attorneys to discuss their rights and options. Ademi LLP can be reached toll-free at 866-264-3995 or via email at gademi@ademilaw.com . Halper Sadeh LLC can be reached at (212) 763-0060 or via email at sadeh@halpersadeh.com or zhalper@halpersadeh.com . Monteverde & Associates PC can be contacted at (212) 971-1341 or via email at jmonteverde@monteverdelaw.com . Kahn Swick & Foti, LLC Managing Partner Lewis S. Kahn can be reached toll free at 855-768-1857 or via email at lewis.kahn@ksfcounsel.com . The firms handle matters on a contingent fee basis.

Bio-Techne has received downgrades from three major financial firms, moving the stock from positive ratings to neutral stances. Benchmark analyst Robert Wasserman downgraded the stock from Buy to Hold. Citigroup analyst Patrick Donnelly also downgraded the stock from Buy to Neutral. Additionally, TD Cowen analyst Kyle Boucher downgraded Bio-Techne from Buy to Hold. These rating actions indicate that the firms no longer expect Bio-Techne to outperform its peers or the market index in the near term.

TD Cowen raised its price target from $65 to $73 alongside the rating change. Citigroup also adjusted its price target to $73 from a previous target of $70. Benchmark did not provide a specific price target in its report. Bio-Techne trades on the NASDAQ under the ticker symbol TECH.